Neuralstem, Inc. (NASDAQ:CUR) Files An 8-K Regulation FD DisclosureItem 7.01. Regulation FD Disclosure.
On July 25, 2017, Neuralstem, Inc. (the “Company”) announced top-line results from its exploratory Phase 2 clinical trial examining the efficacy of NSI-189 for the treatment of major depressive disorder. The study did not meet its primary efficacy endpoint. However, of the two secondary efficacy endpoints analyzed so far, the study achieved statistical significance of the patient-rated symptoms of depression questionnaire. A copy of the press release is attached to this report as Exhibit 99.01.
The information contained in this Item 7.01 to this Current Report on Form 8-K and the exhibit attached hereto pertaining to this item shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information or such exhibits be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information set forth in the exhibits to this Form 8-K relating to this item 7.01 shall not be deemed an admission as to the materiality of any information in this report that is required to be disclosed solely to satisfy the requirements of Regulation FD.
Item 9.01. Financial Statements and Exhibits.
| Exhibit | |
| No. | Description |
| 99.01 | Press Release dated July 25, 2017 |
Neuralstem, Inc. ExhibitEX-99.01 2 exh_9901.htm EXHIBIT 99.01 EdgarFilingEXHIBIT 99.01Neuralstem Announces Top-line Phase 2 Data of NSI-189 for Major Depressive Disorder GERMANTOWN,…To view the full exhibit click here
About Neuralstem, Inc. (NASDAQ:CUR)
Neuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company’s technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company’s NSI-566 is indicated for amyotrophic lateral sclerosis (ALS), chronic spinal cord injury and motor deficits due to ischemic stroke.
